Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Objectives/hypothesis: To determine the prognostic value of hypoxia-associated markers carbonic anhydrase-9 (CA-9) and hypoxia-inducible factor-1α (HIF-1α) in advanced larynx and hypopharynx squamous cell carcinoma (SCCa) treated by organ preservation strategies.
Study Design: Retrospective cohort study.
Methods: Pretreatment CA-9 and HIF-1α expression, clinicopathologic data, and tumor volume were analyzed in a series of 114 patients with T3-4 SCCa larynx or hypopharynx treated by (chemo)radiation.
Results: Adverse prognostic factors for locoregional control were T4 classification (P = 0.008), and for disease-specific survival were CA-9 positivity (P = 0.039), T4 classification (P = 0.001), larger tumor volume (P = 0.004), N1-3 classification (P = 0.002), and pretreatment hemoglobin < 13.0 g/dl (P = 0.014). With increasing CA-9 expression, there was a trend to increasing tumor recurrence (P trend = 0.009) and decreasing survival (P trend = 0.002). On multivariate analysis, independent variables were T4 classification (hazard ratio [HR] 13.54, P = 0.01) for locoregional failure, and CA-9 positivity (HR = 8.02, P = 0.042) and higher tumor volume (HR = 3.33, P = 0.007) for disease-specific mortality.
Conclusion: This is the first study to look specifically at T3 and T4 SCCa larynx and hypopharynx for a relationship between hypoxia-associated marker expression and clinical outcome. Pretreatment immunohistochemical CA-9 expression is an adverse prognostic factor for disease-specific survival, indicating that CA-9 expression may confer a more aggressive tumor phenotype.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1002/lary.24933 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Purpose: TrilynX was a randomized, double-blind, phase III study evaluating the addition of xevinapant (an inhibitor of apoptosis proteins inhibitor) or placebo to chemoradiotherapy (CRT) in patients with unresected locally advanced squamous cell carcinoma of the head and neck (LA SCCHN).
Methods: Patients with unresected LA SCCHN (oropharynx [p16-negative only], hypopharynx, or larynx) were randomly assigned 1:1 to six cycles of oral xevinapant 200 mg/day or matched placebo (once daily on Days 1-14 of a 21-day cycle) plus CRT for the first three cycles (cisplatin [100 mg/m once on Day 2 of every cycle] plus intensity-modulated radiotherapy [70 Gy; 35 fractions of 2 Gy/day, 5 days/week]). The primary end point was event-free survival (EFS) assessed by the blinded independent review committee.
Pre-treatment PET/CT for head and neck squamous cell carcinoma: secondary analysis of a clinical trial.
Oral Oncol
August 2025
Wayne State University Department of Otolaryngology-Head and Neck Surgery, Detroit, MI, USA; Karmanos Cancer Institute, Detroit, MI, USA. Electronic address:
Objective: This study aims to evaluate the influence of pre-treatment PET/CT imaging on survival outcomes in individuals with locally advanced head and neck squamous cell carcinoma (HNSCC) STUDY DESIGN: Secondary analysis of the Radiation Therapy Oncology Group 0522 trial.
Setting: Phase III randomized clinical trial with multi-institutional enrollment.
Methods: Of the 940 patients enrolled, 891 met inclusion criteria and were included in the analysis.
Opening of a phase Ib/II study to investigate the safety and efficacy of Afatinib in patients with Fanconi anemia and unresectable locally advanced or metastatic head and neck squamous cell carcinoma.
BMC Cancer
August 2025
Institut de Recerca Sant Pau (IR SANT PAU) and Joint Research Unit on Genomic Medicine, Universitat Autònoma de Barcelona (UAB)-IR SANT PAU, Barcelona, Spain.
Background: Individuals diagnosed with Fanconi anemia (FA) present an incidence of 500- to 700-fold higher to develop head and neck squamous carcinomas (HNSCCs) compared to the general population. Effective anticancer treatments for FA-HNSCCs are missing. Several studies demonstrated that FA-HNSCCs overexpress the epithelial growth factor receptor (EGFR) and their viability is highly dependent on this pathway, as FA-HNSCCs cells are highly sensitive to EGFR inhibitors such as afatinib in preclinical models, which led to an orphan drug designation by EMA in 2018.
View Article and Find Full Text PDFThe lymph node ratio is a prognostic factor for survival in laryngeal and hypopharyngeal squamous cell carcinoma.
Oral Oncol
August 2025
Department of Otolaryngology - Head and Neck Surgery, St. James' Hospital, Dublin, Ireland; University of Dublin, Trinity College, Dublin, Ireland.
Introduction: The lymph-node yield and the lymph-node ratio have emerged as important prognostic tools for head and neck cancer. These metrics are an index of disease burden, but also of quality standards. The objective of the present study was to examine the impact of different lymph-node yield cut-offs and the lymph-node ratio on 10-year recurrence-free interval and overall-survival.
View Article and Find Full Text PDFRecent advances in PET/MR imaging for head and neck tumors: a systematic review of the last three years.
Radiol Med
August 2025
Department of Nuclear Medicine, University Hospital Zurich, University of Zurich, Zurich, Switzerland.
Purpose: This systematic review addresses the clinical relevance of PET/MR in patients with head and neck (HN) tumors, highlighting studies conducted over the last three years to provide an updated perspective on integrating a hybrid PET/MR scan into different clinical scenarios.
Methods: We employed a search algorithm, combining terms ("PET/MR" OR ("PET" AND ("MR" OR "MRI")) OR "PET/MRI" OR "PET-MR" OR "PET-MRI" OR ("PET" AND "magnetic")) AND ("head" AND "neck"). Studies written in English and published throughout 2021, 2022 and 2023 up to November 15th were considered if were focused on: suspected HN tumors; confirmed HN tumors before surgery/radiotherapy/chemotherapy; HN tumor recurrence or therapy response assessment.